Clinical trial · Interventional
Chemoembolization for Lung Tumors
Phase I Study of Transarterial Chemoembolization of Lung Metastases
NCT04200417CI-TRIAL-00089834completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to determine if it is safe to perform lung chemoembolization and if the lung chemoembolization procedure can successfully deliver chemotherapy to lung tumors.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endobronchial Metastases | — | UNRESOLVED | — |
| Lung Metastases | — | UNRESOLVED | — |
| Mediastinal Metastases | — | UNRESOLVED | — |
| Pleural Metastases | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemoembolization | Procedure | — | UNRESOLVED |
| Embospheres | Drug | — | UNRESOLVED |
| Lipiodol | Drug | — | UNRESOLVED |
| Mitomycin C | Drug | Mitomycin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Lung, Endobronchial, Mediastinal or Pleural Metastases
- description
- Participants will have unresectable and unablatable lung, endobronchial, mediastinal, or pleural metastases (from any primary) that are not responding to chemotherapy
- interventionNames
- Procedure: Chemoembolization
- Drug: Mitomycin C
- Drug: Lipiodol
- Drug: Embospheres
Primary outcomes (1)
- measure
- Participant toxicity will be evaluated according to CTCAE v5.0
- timeFrame
- Up to 12 months post treatment
- description
- Safety will be evaluated by participant toxicity according to CTCAE v5.0
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Lung, endobronchial, pleural, or mediastinal metastases that are not responding to systemic chemotherapy, and that are not amenable to ablation, resection, or SBRT. * At least 18 years old. * ECOG performance status 0 or 1 Exclusion Criteria: * Primary lung cancer * \>50% of a lung is replaced with tumor * Oxygen saturation \<92% on room air * FEV1 \<60% * Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, MRI, or direct pressure measurement) * Recent pulmonary embolism (within 3 months) * Pulmonary arteriovenous malformation * Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month) * Symptomatic heart failure (dyspnea, volume overload) * Left bundle branch block (contraindication to pulmonary angiography) * Renal failure (eGFR \<30 mL/min/1.73m\^2) * Pregnancy * Breastfeeding * Altered mental status that would interfere with consent or follow-up * Platelets \< 100,000 (after transfusion, if needed) * INR\>2 (after transfusion, if needed) * Hemoglobin \<7 (after transfusion, if needed) * Hyperthyroidism (contraindication to lipiodol) * Planned radioactive iodine imaging or therapy (contraindication to lipiodol) * Allergy to lipiodol or mitomycin * Allergy to iodinated contrast that can not be treated with steroid / diphenhydramine premedication * Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
References
Publications (0)
Data not yet available
No reference posted for this study.